- Home
- AMC vs AGIO Comparison
AMC vs AGIO Comparison
Compare AMC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- AGIO
- Stock Information
- Founded
- AMC 1920
- AGIO 2007
- Country
- AMC United States
- AGIO United States
- Employees
- AMC N/A
- AGIO N/A
- Industry
- AMC Movies/Entertainment
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- AMC Consumer Discretionary
- AGIO Health Care
- Exchange
- AMC Nasdaq
- AGIO Nasdaq
- Market Cap
- AMC 1.3B
- AGIO 1.4B
- IPO Year
- AMC 2013
- AGIO 2013
- Fundamental
- Price
- AMC $2.86
- AGIO $35.00
- Analyst Decision
- AMC Hold
- AGIO Buy
- Analyst Count
- AMC 8
- AGIO 6
- Target Price
- AMC $3.93
- AGIO $57.40
- AVG Volume (30 Days)
- AMC 13.3M
- AGIO 840.6K
- Earning Date
- AMC 08-11-2025
- AGIO 07-31-2025
- Dividend Yield
- AMC N/A
- AGIO N/A
- EPS Growth
- AMC N/A
- AGIO N/A
- EPS
- AMC N/A
- AGIO N/A
- Revenue
- AMC $4,548,300,000.00
- AGIO N/A
- Revenue This Year
- AMC $8.34
- AGIO $18.94
- Revenue Next Year
- AMC $6.61
- AGIO $201.70
- P/E Ratio
- AMC N/A
- AGIO $3.15
- Revenue Growth
- AMC N/A
- AGIO 36.07
- 52 Week Low
- AMC $2.45
- AGIO $23.42
- 52 Week High
- AMC $5.56
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- AMC 38.30
- AGIO 38.99
- Support Level
- AMC $3.08
- AGIO $37.09
- Resistance Level
- AMC $3.39
- AGIO $39.12
- Average True Range (ATR)
- AMC 0.15
- AGIO 1.78
- MACD
- AMC -0.06
- AGIO -0.67
- Stochastic Oscillator
- AMC 2.63
- AGIO 9.16
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.